Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
2-acetyl-4-(tetrahydroxybutyl)imidazole (THI) is a small molecule inhibitor of sphingosine 1-phosphate (S1P) lyase. It is a chemical constituent found in ammonia caramel food coloring (E 150c). THI exerts immunomodulatory effects by inhibiting the irreversible degradation of S1P, which increases S1P levels in lymphoid tissues and disrupts the S1P gradient between tissues and blood. This disruption leads to the sequestration of lymphocytes in non-lymphoid tissues and the thymus, resulting in peripheral lymphopenia. THI has been investigated in preclinical models for the treatment of autoimmune and inflammatory conditions, including type 1 diabetes and Crohn's-like ileitis. It has also been reported to inhibit pyridoxal kinase and has undergone Phase 2 clinical evaluation for rheumatoid arthritis.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on 2-acetyl-4-(tetrahydroxybutyl)imidazole.